https://ogma.newcastle.edu.au/vital/access/manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:50976 Wed 31 Jul 2024 09:13:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46789 Wed 30 Nov 2022 13:21:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46762 Wed 30 Nov 2022 10:19:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:53996 Wed 28 Feb 2024 16:39:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:51366 Wed 28 Feb 2024 15:46:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:52387 Wed 28 Feb 2024 15:38:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:50523 Wed 28 Feb 2024 15:17:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:50584 Wed 28 Feb 2024 15:06:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:47871  0.5 and diabetes comorbidity were the most significant predictors of hypertension presence, awareness and treatment. Individuals with diabetes were twice as likely to have hypertension, 7.0 times more likely to be aware, 3.3 times more likely to be on antihypertensive medication, and 2.4 times more likely to be controlled on medication. Women and individuals reporting lower salt use were more likely to be aware and treated for hypertension. Applying the 2017 AHA/ACC hypertension guidelines showed only 1 in 4 adults had normal BP. As with HIV, similarly intensive efforts are now needed in the region to improve non-communicable disease diagnosis and management.]]> Wed 28 Feb 2024 14:59:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46444 Wed 23 Nov 2022 13:56:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:27361 Wed 23 Feb 2022 16:04:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:55372 Wed 22 May 2024 15:00:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:53289 Wed 21 Aug 2024 11:13:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54897 Wed 20 Mar 2024 13:32:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:36840 Wed 19 Jan 2022 15:17:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:42037 Wed 17 Aug 2022 12:13:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:55332 Wed 15 May 2024 15:46:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:37079 Wed 15 Dec 2021 16:07:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:51233 Wed 13 Mar 2024 13:56:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:39633 N = 1265) was undertaken using self-report data derived from a cross-sectional telephone survey of Australian adults, undertaken in 2017. Results: Fifteen per cent (n = 184) of participants identified as having a mental health condition in the past 12 months. Across most (7 of 8) sleep parameters, the prevalence of suboptimal sleep was higher among people with a mental health condition, compared to those without (all p < 0.05). The highest prevalence of suboptimal sleep for both groups was seen on measures of sleep duration (36–39% and 17–20% for people with and without a mental health condition, respectively). In terms of sleep assessment and treatment, people with a mental health condition were significantly more likely to: desire treatment (37% versus 16%), have been assessed (38% versus 12%) and have received treatment (30% versus 7%). Conclusions: The prevalence of suboptimal sleep among persons with a mental health condition in Australia is significantly higher than those without such a condition, and rates of assessment and treatment are low for both groups, but higher for people with a mental health condition. Population health interventions, including those delivered as part of routine health care, addressing suboptimal sleep are needed.]]> Wed 13 Mar 2024 08:54:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:53701 Wed 10 Jan 2024 10:48:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:36077 Haemophilus influenzae is the most commonly identified bacteria. Haemophilus influenzae is divided into typeable and nontypeable (NTHi) strains based on the presence or absence of a polysaccharide capsule. While NTHi is a common commensal in the human nasopharynx, it is associated with considerable inflammation when it is present in the lower airways of COPD patients, resulting in morbidity due to worsening symptoms and increased frequency of COPD exacerbations. Treatment of lower airway NTHi infection with antibiotics, though successful in the short term, does not offer long-term protection against reinfection, nor does it change the course of the disease. Hence, there has been much interest in the development of an effective NTHi vaccine. This review will summarize the current literature concerning the role of NTHi infections in COPD patients and the consequences of using prophylactic antibiotics in patients with COPD. There is particular focus on the rationale, findings of clinical studies and possible future directions of NTHi vaccines in patients with COPD.]]> Wed 09 Feb 2022 15:54:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:52951 Wed 07 Feb 2024 14:35:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:51661 Wed 07 Feb 2024 14:30:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54629 Wed 06 Mar 2024 10:52:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:53517 Wed 03 Apr 2024 15:23:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:45583 Wed 02 Nov 2022 10:33:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46635 JCI, Karcz et al. identified a mechanism involving the nucleotide sugar UDP-glucose (UDP-G) and the purinergic receptor P2Y₁₄R in amplifying eosinophil accumulation in the lung. During type 2 inflammation, UDP-G activates P2Y₁₄R on eosinophils, inducing the cells to move and migrate into the lung. Pharmacologically or genetically inhibiting P2Y₁₄R on eosinophils attenuated eosinophil infiltration and AHR. Future experiments, including identifying additional type 2 factors regulating P2Y₁₄R expression on lung eosinophils, are necessary to ascertain the impact of targeting P2Y₁₄R as an alternative or adjunctive therapy to current type 2 biologics for the treatment of asthma.]]> Tue 29 Nov 2022 10:35:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54455 Tue 27 Feb 2024 13:53:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:36663 Tue 23 Jun 2020 11:12:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54385 Tue 20 Feb 2024 20:46:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:41920 0.7. Despite defined cut-off values, no jurisdiction prescribes a reference equation for use; multiple equations exist. We hypothesized that access to subsidized treatment varies depending on the chosen equation. The %FVC and %TLco from different commonly used reference equations across general respiratory patients, and IPF-specific patients, were compared. Methods: FVC and TLco measurements from a large general respiratory laboratory and the Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR) database were analysed using multiple equations. Differences between %FVC and %TLco for each equation were calculated, with particular interest in classification of patients (%) at the threshold for subsidized treatment. Results: A total of 20 378 general respiratory database results were analysed. The %FVC ≥ 50% increased from 86% with the Roca equation to 96% with Quanjer (European Coal and Steal Community, ECSC) and %TLco≥30% increased from 91% with Paoletti to 98% with Thompson. However, overall increase in eligibility for subsidized treatment was modest, varying from 48.2% to 49.2%. A total of 545 AIPFR database results were analysed. The %FVC ≥ 50% increased from 73% with Roca to 94% with Quanjer (ECSC) and %TLco≥30% increased from 87% with Paoletti to 96% with Miller. Overall eligibility for subsidized treatment in the AIPFR group varied from 73.6% to 82.8% between surveyed interstitial lung disease (ILD) centres based entirely on the equation used. Conclusion: Substantial variability exists between reference equations, impacting access to subsidized treatment. Treating clinicians should be aware of this when assessing patients around public funding thresholds.]]> Tue 16 Aug 2022 11:07:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:48331 75% for each characteristic) would not modify duration based on host characteristics such as patient age or co-morbidities. ID physicians recommended longer durations than ICU physicians for all five syndromes (ID, median 10, IQR 7–14, range 1–28 days; ICU, median 7, IQR 5–10, range 2–21 days). Across all respondents, the median (IQR) duration for each syndrome was: CVC-BSI, 7 (7–10) days; bacteraemic pneumonia, 7 (7–10) days; bacteraemic UTI, 10 (7–14) days; bacteraemic IAI, 7 (7–12) days; and bacteraemic SSTI, 10 (7–14) days. Marked variation exists amongst clinicians’ recommended duration of antibiotic treatment for BSI. A proportion of clinicians recommend therapy of ≤7 days at present (33.3–59.7% across scenarios). Patient characteristics are not strongly considered in the decision on therapy duration. This survey was undertaken as preparatory work for initiation of the BALANCE study, an ongoing randomised trial comparing 7 days with 14 days of therapy for BSI, providing an evidence base to inform best clinical treatment for this patient population.]]> Tue 14 Mar 2023 16:54:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54232 Tue 13 Feb 2024 12:28:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:47240 Tue 13 Aug 2024 11:54:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:49801 Tue 10 Sep 2024 10:21:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:38188 Tue 10 Aug 2021 15:11:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:42861 n = 309) were predominantly female (61%), from the obese BMI category (67%) and had accessed a range of services for weight loss (97%). Using multiple logistic regression, participants with higher mYFAS scores were more likely to engage in treatment (AOR 1.68; 95% CI 1.12–2.52), while participants with higher DASS total scores were less likely to engage in treatment (AOR 0.97; 95% CI 0.95–0.99). Conclusion: This study indicates considerable interest from consumers in seeking addictive eating treatment. Individuals who did not engage in treatment displayed higher mental health comorbidity, suggesting that higher mental health symptomatology may be a barrier to treatment. Future qualitative research is needed to provide an in-depth understanding of the reasons for seeking and engaging in addictive eating treatment, as well as to identify the optimal treatments and referral pathways. Level of evidence: Level IV.]]> Tue 06 Sep 2022 09:10:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:45873 Tue 06 Dec 2022 09:32:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:43825 Tue 04 Oct 2022 11:04:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:33201 Thu 28 Oct 2021 13:03:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:45316 Thu 27 Oct 2022 13:31:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:35013 Thu 24 Mar 2022 11:29:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:51870 Thu 21 Sep 2023 10:24:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:47431 Thu 19 Jan 2023 16:19:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:48437 Thu 16 Mar 2023 14:25:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:43260 Thu 15 Sep 2022 11:06:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54268 Thu 15 Feb 2024 14:31:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:48866 Thu 13 Apr 2023 10:01:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:49312 Thu 11 May 2023 14:39:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:55950 Thu 11 Jul 2024 15:09:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:38357 Thu 09 Sep 2021 12:21:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:47934 Thu 09 Feb 2023 15:43:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:40274 Thu 07 Jul 2022 12:58:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:44094 3 seconds perfusion lesion with severely delayed contrast transit (delay time >3 seconds/delay time >6 seconds). Results: There were 306 patients included in this study. With every increase of 10 mmHg in baseline systolic blood pressure, the odds of achieving an excellent functional outcome decreased by 12% in multivariate analysis (odds ratio = 0.88, p = 0.048). Conversely, increased baseline blood pressure was associated with better collateral flow. In subgroup analysis of patients with major reperfusion, higher blood pressure was associated with decreased infarct growth and a better clinical outcome, and vice versa in patients without reperfusion. Interpretation: Higher baseline blood pressure in acute ischemic stroke patients with large vessel occlusion/stenosis was associated with better collateral flow. However, for patients without reperfusion, higher baseline blood pressure was associated with increased infarct growth, leading to an unfavorable clinical outcome. The relationship between blood pressure and outcomes is highly dependent on reperfusion, and active blood pressure–lowering treatment may be inappropriate in acute ischemic stroke patients prior to reperfusion treatment.]]> Thu 06 Oct 2022 16:16:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:36115 Thu 06 Feb 2020 16:38:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:55798 23.7% risk of incident N1b disease). Conclusions: A small number of PTMCs may recur, and the presence of involved lymph nodes at diagnosis is a predictive factor. In this study, the presence of N1b disease at diagnosis was the strongest predictor of future recurrence. However, N1a disease, especially with >5 involved N1a nodes, was also predictive.]]> Sat 22 Jun 2024 12:47:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:49523 Sat 20 May 2023 12:39:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:50597 Mon 31 Jul 2023 10:30:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:38784 Mon 31 Jan 2022 14:00:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:52865 Mon 30 Oct 2023 10:01:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:49703 Mon 29 May 2023 13:00:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:38383 Mon 29 Jan 2024 17:45:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54031 25 years to <60 years) to be referred for outpatient psychiatric care following self-harm. More recent studies were associated with a small increase in the proportion of presentations (events) that were referred to, and received, psychiatric outpatient treatment. No macro-level factor explained between-study heterogeneity. Interpretation: There is considerable scope for improvement in the allocation and provision of both in- and out-patient psychiatric care following hospital-presenting self-harm, particularly considering that the period after discharge from general hospitals represents the peak risk period for repeat self-harm and suicide. Given the marked between-study heterogeneity, the basis for allocation of aftercare treatment is therefore not yet known and should be further studied. Funding: There was no specific funding for this review.]]> Mon 29 Jan 2024 13:33:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:38003 Mon 28 Feb 2022 09:30:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:44733 Mon 24 Oct 2022 08:28:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:50387 75 % of participant agreement. Results: The consensus DOOR comprised four main dimensions. The primary dimension was patient-reported joint function. The secondary dimensions were infection cure and mortality. The final dimension of quality of life was selected as a tie-breaker. Discussion: A desirability of outcome ranking for periprosthetic joint infection has been proposed. It focuses on patient-centric outcome measures of joint function, cure and quality of life. This DOOR provides a multidimensional assessment to comprehensively rank outcomes when comparing treatments for prosthetic joint infection.]]> Mon 24 Jul 2023 14:12:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:27031 Mon 23 Sep 2019 12:39:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:25507 Mon 23 Sep 2019 12:29:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:33901 Mon 23 Sep 2019 12:18:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:42358 Mon 22 Aug 2022 14:01:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:53249 Mon 20 Nov 2023 10:28:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:48484 Mon 20 Mar 2023 11:02:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:41915 14). Limitations: The lack of a control group and the absence of a complete clinical assessment at the follow-up limit the interpretability of our results. Conclusions: Our data driven analysis suggest insomnia heterogeneity can be categorized into sub-classes by depression, anxiety, and stress symptoms. In addition, insomnia patients with stress and depression symptoms maintained highest percentage of clinical depression at the end-of-treatment and insomnia at follow-up, in comparison with others classes. Stress and depression symptoms should be considered risk factors that play an important role in the long-term outcome of CBT-I.]]> Mon 15 Aug 2022 16:00:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46202 vs 5/48 [10%], P = 0.0006). The need for parenteral sedation to manage acute behavioural disturbance following naloxone provision was rare (3/117 [3%]). Conclusions: In this retrospective observational study, a single large i.m. dose of naloxone reversed the toxicity of suspected heroin overdose in the majority of patients. In addition, patients were less likely to require repeated intermittent doses or naloxone infusion than those treated solely with i.v. naloxone. Further comparison in a prospective study is warranted to validate these observations in confirmed heroin overdose. Requirement for sedation secondary to acute behavioural disturbance was rare regardless of the route.]]> Mon 14 Nov 2022 11:22:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:54195 Mon 12 Feb 2024 14:43:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:56182 Mon 12 Aug 2024 10:11:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:44221 Mon 10 Oct 2022 16:59:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:40997 25 kg/m²) with addictive eating as defined by the modified Yale Food Addiction Scale (mYFAS) were recruited to a three-session intervention held over 3 months. Sessions were conducted by telehealth and facilitated by dietitians. Fifty-two individuals were randomised to either intervention or control (mean age 43.6 ± 12.2yrs, mean BMI 36.7 ± 6.8 kg/m², 96% female). At three month follow up, there were significant reductions from baseline (BL) for both groups in total YFAS 2.0 symptoms, however, these changes were not significantly different between groups (intervention BL 8.0 ± 2.7; 3-months 6.5 ± 3.8, control BL 8.1 ± 2.5; 3-months 6.9 ± 3.9, p > 0.05). At 3 months the intervention group significantly reduced their energy from non-core foods compared with control (intervention BL 48% energy/day; 3-months 38%, control BL 41% energy/day; 3-months 38%, p < 0.01). The FoodFix intervention provides insight to the development of future management interventions for addictive eating.]]> Mon 08 Aug 2022 14:43:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46876 International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) and were seeking treatment, were nonresponsive to prior treatment attempts, were 18 to 64 years of age, had no other substance use disorder, had no severe medical or psychiatric conditions, were not pregnant, were not mandated by a court to undergo treatment, and provided informed consent. Results for primary efficacy measures and all secondary outcomes were obtained using a modified intention-to-treat data set. Interventions: Participants received 12-week treatment involving weekly clinical reviews, structured counseling, and flexible medication doses - up to 32 sprays daily (tetrahydrocannabinol, 86.4 mg, and cannabidiol, 80 mg), dispensed weekly. Main Outcomes and Measures: Primary outcome was self-reported number of days using illicit cannabis during the 12-week period. Other outcomes included alternate cannabis use parameters (periods of abstinence, withdrawal, cravings, and problems), safety parameters (adverse events and aberrant medication use), health status, other substance use, and treatment retention. Results: A total of 128 participants (30 women and 98 men; mean [SD] age, 35.0 [10.9] years) were randomized and received at least 1 dose of study medication. Participants had used a mean (SD) of 2.3 (2.1) g of cannabis on a mean (SD) of 25.7 (4.5) days in the past 28 days. Treatment retention was comparable for the 2 groups (placebo, 30 of 67 participants [44.8%]; nabiximols, 30 of 61 participants [49.2%]), and both groups used similar mean (SD) doses (placebo, 18.5 [9.5] sprays daily; nabiximols, 17.6 [9.5] sprays daily, equivalent to a mean [SD] of 47.5 [25.7] mg of tetrahydrocannabinol and 44.0 [23.8] mg of cannabidiol). For the primary end point, the placebo group reported significantly more days using cannabis during the 12 weeks (mean [SD], 53.1 [33.0] days) than the nabiximols group (mean [SD], 35.0 [32.4] days; estimated difference, 18.6 days; 95% CI, 3.5-33.7 days; P =.02). Both groups showed comparable improvements in health status, with no substantial changes in other substance use. Medication was well tolerated with few adverse events. Conclusions and Relevance: This study demonstrates that cannabinoid agonist treatment, in this case using nabiximols, in combination with psychosocial interventions is a safe approach for reducing cannabis use among individuals with cannabis dependence who are seeking treatment. Trial Registration: anzctr.org.au Identifier: ACTRN12616000103460.]]> Mon 05 Dec 2022 09:33:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:41261 Mon 01 Aug 2022 09:21:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:45488 Fri 28 Oct 2022 14:57:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:45478 65 years of age) presented with stage I-III pancreatic cancer. The majority of patients had tumors >2 cm size (82%), grade I/II (65%), lymphatic invasion (LI) (66%), and negative margins (76%). A survival advantage for adjuvant therapy was observed among all patients, independent of their risk-profile. For example, a patient =65 years of age, with early stage cancer (size =2 cm, grade I/II, -ve LI, -ve margins) who received adjuvant therapy had a 62% probability of being alive beyond three years (95%CI = 59%-66%). In contrast, the survival probability decreased to 53% (95%CI = 59%-66%) without adjuvant therapy. Conclusions: These results provide surgeons and patients with more accurate information regarding long-term survival, as well as the benefit of opting for adjuvant therapy after successful pancreatic surgery.]]> Fri 28 Oct 2022 14:36:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:45413 Fri 28 Oct 2022 12:09:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:52787 Fri 27 Oct 2023 09:47:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:37583 16 years), who presented with a confirmed snakebite from August 2013 to October 2014 were recruited from Anuradhapura Hospital. Demographic data, information on the circumstances of the bite, first aid, health-seeking behaviour, hospital admission, clinical features, outcomes and antivenom treatment were documented prospectively. There were 742 snakebite patients [median age: 40 years (IQR:27–51; males: 476 (64%)]. One hundred and five (14%) patients intentionally delayed treatment by a median of 45min (IQR:20-120min). Antivenom was administered a median of 230min (IQR:180–360min) post-bite, which didn’t differ between directly admitted and transferred patients; 21 (8%) receiving antivenom within 2h and 141 (55%) within 4h of the bite. However, transferred patients received antivenom sooner after admission to Anuradhapura hospital than those directly admitted (60min [IQR:30-120min] versus 120min [IQR:52-265min; p<0.0001]). A significantly greater proportion of transferred patients had features of systemic envenoming on admission compared to those directly admitted (166/212 [78%] versus 5/43 [12%]; p<0.0001), and had positive clotting tests on admission (123/212 [58%] versus 10/43 [23%]; p<0.0001). Sri Lankan snakebite patients present early to hospital, but there remains a delay until antivenom administration. This delay reflects a delay in the appearance of observable or measurable features of envenoming and a lack of reliable early diagnostic tests. Improved early antivenom treatment will require reliable, rapid diagnostics for systemic envenoming.]]> Fri 23 Aug 2024 12:47:45 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:37574 Fri 19 Feb 2021 15:23:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:53140 Fri 17 Nov 2023 11:42:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:39683 Fri 17 Jun 2022 15:46:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:35921 Fri 17 Jan 2020 09:36:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:44495 Fri 14 Oct 2022 09:46:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:55676 Fri 14 Jun 2024 13:50:00 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:37082 Fri 14 Aug 2020 14:27:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:47367 Fri 13 Jan 2023 14:57:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:46107 −2) versus healthy-weight (BMI <25 kg·m⁻²) subjects with asthma. Design Databases including CINAHL (Cumulative Index to Nursing and Allied Health Literature), Cochrane, Embase and MEDLINE were searched up to July 2019 for English-language studies that recorded medication use or dose in obese and healthy-weight adults with asthma. A critical appraisal checklist was utilised for scrutinising methodological quality of eligible studies. Meta-analysis was performed and heterogeneity was examined with the use of the Chi-squared test. This review was conducted based on a published protocol (www.crd.york.ac.uk/PROSPERO CRD42020148671). Results Meta-analysis showed that obese subjects are more likely to use asthma medications, including short-acting β2-agonists (OR 1.75, 95% CI 1.17–2.60; p=0.006, I²=41%) and maintenance oral corticosteroids (OR 1.86, 95% CI 1.49–2.31; p<0.001, I2=0%) compared to healthy-weight subjects. Inhaled corticosteroid (ICS) dose (µg·day⁻¹) was significantly higher in obese subjects (mean difference 208.14, 95% CI 107.01–309.27; p<0.001, I²=74%). Forced expiratory volume in 1 s (FEV₁) % predicted was significantly lower in obese subjects (mean difference −5.32%, 95% CI −6.75–−3.89; p<0.001, I²=42%); however, no significant differences were observed in FEV₁/forced vital capacity (FVC) ratio between groups. Conclusions We found that obese subjects with asthma have higher use of all included asthma medication classes and higher ICS doses than healthy-weight asthma subjects, despite lower FEV₁ and a similar FEV₁/FVC %. A better understanding of the factors driving increased medication use is required to improve outcomes in this subgroup of asthmatics.]]> Fri 11 Nov 2022 15:35:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:43014 Fri 09 Sep 2022 16:16:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:49142 Fri 05 May 2023 12:07:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:50749 Fri 04 Aug 2023 10:45:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/manager/Repository/uon:36583 Fri 01 Apr 2022 09:23:30 AEDT ]]>